ADC Therapeutics SA

23.99-1.83-7.09%Vol 181.57K1Y Perf -18.75%
Apr 9th, 2021 16:00 DELAYED
BID23.66 ASK24.59
Open25.77 Previous Close25.82
Pre-Market- After-Market-
 - -  - -%
Target Price
48.00 
Analyst Rating
— — 0.00
Potential %
100.08 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.65B 
Earnings Rating
Price Range Ratio 52W %
7.07 
Earnings Date
18th Mar 2021

Today's Price Range

23.5725.77

52W Range

21.5156.59

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-6.00%
1 Month
-3.46%
3 Months
-26.59%
6 Months
-29.11%
1 Year
-18.75%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ADCT23.99-1.8300-7.09
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.68-0.73-7.35
Q03 2020-0.77-0.2962.34
Q02 2020-0.96-0.7126.04
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.68
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume181.57K
Shares Outstanding68.89M
Trades Count1.90K
Dollar Volume4.54M
Avg. Volume305.49K
Avg. Weekly Volume216.09K
Avg. Monthly Volume485.75K
Avg. Quarterly Volume310.64K

ADC Therapeutics SA (NYSE: ADCT) stock closed at 23.99 per share at the end of the most recent trading day (a -7.09% change compared to the prior day closing price) with a volume of 181.58K shares and market capitalization of 1.65B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 138 people. ADC Therapeutics SA CEO is .

The one-year performance of ADC Therapeutics SA stock is -18.75%, while year-to-date (YTD) performance is -25.05%. ADCT stock has a five-year performance of %. Its 52-week range is between 21.51 and 56.59, which gives ADCT stock a 52-week price range ratio of 7.07%

ADC Therapeutics SA currently has a PE ratio of -6.80, a price-to-book (PB) ratio of 5.58, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -75.62%, a ROC of -45.77% and a ROE of -110.28%. The company’s profit margin is -%, its EBITDA margin is -4 876.10%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from ADC Therapeutics SA, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.68 for the next earnings report. ADC Therapeutics SA’s next earnings report date is -.

The consensus rating of Wall Street analysts for ADC Therapeutics SA is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for ADC Therapeutics SA stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ADC Therapeutics SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ADC Therapeutics SA has a Sell technical analysis rating based on Technical Indicators (ADX : 21.90, ATR14 : 2.14, CCI20 : -82.45, Chaikin Money Flow : -0.19, MACD : -1.78, Money Flow Index : 26.17, ROC : -15.85, RSI : 39.96, STOCH (14,3) : 41.35, STOCH RSI : 1.00, UO : 38.38, Williams %R : -58.65), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ADC Therapeutics SA in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

ADC Therapeutics SA

ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.

CEO:

Telephone: +41 216530200

Address: Route de la Corniche 3B, Epalinges 1066, , CH

Number of employees: 138

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

55%45%

Bearish Bullish

67%33%

News

Stocktwits